ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
2
views
0
references
Top references
cited by
0
Cite as...
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
1,170
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
Tildrakizumab efficacy over time stratified by week-28 response levels and by prior biologic use
Publication date
Created:
October 2019
Publication date
(Print):
October 2019
Journal:
Journal of the American Academy of Dermatology
Publisher:
Elsevier BV
Read this article at
ScienceOpen
Publisher
Review
Review article
Invite someone to review
Bookmark
Cite as...
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Efficacy of Communicating Science
Author and article information
Journal
Title:
Journal of the American Academy of Dermatology
Abbreviated Title:
Journal of the American Academy of Dermatology
Publisher:
Elsevier BV
ISSN (Print):
01909622
Publication date Created:
October 2019
Publication date (Print):
October 2019
Volume
: 81
Issue
: 4
Page
: AB136
Article
DOI:
10.1016/j.jaad.2019.06.512
SO-VID:
ce9927f3-3dc9-42af-a77b-d2d5a5cbc1fd
Copyright ©
© 2019
License:
https://www.elsevier.com/tdm/userlicense/1.0/
History
Data availability:
Comments
Comment on this article
Sign in to comment
scite_
Similar content
1,170
Long-term safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis through 3 years (148 weeks) from reSURFACE 1 and reSURFACE 2 phase III trials
Authors:
K Reich
,
DD Thaci
,
L. IVERSEN
Long-term efficacy and safety of tildrakizumab for moderate-to- severe psoriasis: pooled analyses of two ran- domized phase
Authors:
K. REICH
,
RB Warren
,
L Iversen
…
15904 Efficacy and safety of long-term tildrakizumab for plaque psoriasis: 4-year results from reSURFACE 1
Authors:
Jeffrey J. Crowley
,
Neil Korman
,
Lynda Spelman
…
See all similar